Taltz (ixekizumab subcutaneous injection) — Cigna

Reauthorization criteria

• Patient has been established on therapy for at least 6 months; AND
• Patient meets at least ONE of the following (a or b):
• a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating Taltz); OR
• b) Compared with baseline (prior to initiating Taltz), patient experienced an improvement in at least one symptom, such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths.

Approval duration

1 year